ISPOR EXPANDS SCIENTIFIC STAFF BY ADDITION OF CHIEF SCIENCE OFFICER

Published Sep 1, 2015
Princeton, NJ, USA - The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is pleased to announce it is recruiting for a Senior Director & Chief Science Officer, a new position reporting to the Chief Executive Officer & Executive Director.  This position offers an exceptional opportunity to contribute to the continued success of an internationally recognized health economics and outcomes research society. ISPOR’s knowledge products and services include conferences, education, journals, publications, guidelines, and tools used by thousands of global health economists and health care decision makers annually. By focusing on member input and construction of the consensus view of the appropriate path for advancing HEOR science, the successful candidate will develop, lead, support, and direct strategic initiatives related to research, scientific, and content priorities to accomplish the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. The successful candidate will bring to ISPOR extensive experience.  “We look forward to hearing from senior level candidates with deep professional experience, well versed in health economics and outcomes research as well as a passion for ISPOR.  We encourage applications from the global community based on the following position description”, said Nancy Berg, ISPOR CEO & Executive Director. Further details on the position and application details are available at:  ISPOR eJobs Employment Center.

Related Stories

Promoting Fairness in Funding Decisions

Jun 24, 2026

Value in Health announced the publication of a special themed section of research papers that offer new tools to help health policy makers weigh fairness alongside cost-effectiveness when deciding which treatments and programs to fund.

Listening to Patients in the Real World

Jun 23, 2026

Value in Health, the official journal of ISPOR announced today the publication of an ISPOR Good Practices Report outlining 9 areas to strengthen the robustness, transparency, and feasibility of real-world patient-reported outcomes studies.

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×